Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline
Cristiana Sessa(Institute of Oncology Research), Shani Paluch–Shimon(Hebrew University of Jerusalem), D. Fischerová(Charles University), Birthe Lemley(European CanCer Organisation), Nadia Harbeck(Breast Center), Sharon L. Bober(Harvard University), Maria João Cardoso(Champalimaud Foundation), N. Colombo(European Institute of Oncology), Kelly‐Anne Phillips(The University of Melbourne), Ephrat Levy‐Lahad(Hebrew University of Jerusalem), Susan M. Domchek(University City Science Center), Christiane Kühl(Universitätsklinikum Aachen), Jonathan A. Ledermann(London Cancer), Matteo Lambertini(Ospedale Policlinico San Martino), Judith Balmañà(Vall d'Hebron Hospital Universitari), D. Gareth Evans(Manchester Academic Health Science Centre), Sibylle Loibl(Goethe University Frankfurt), Giuseppe Curigliano(European Institute of Oncology)
Cited by 271
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k